Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMRX Chimerix	$8.54	$8.54	$0.75 ▼ $8.55	$801.09M	-0.17	2.91 million shs	N/A
IMAB I-Mab	$2.13 +1.4%	$1.90	$0.60 ▼ $3.08	$173.94M	1.4	390,720 shs	84,023 shs
LENZ LENZ Therapeutics	$33.86 +0.4%	$30.30	$16.54 ▼ $38.93	$953.89M	0.42	198,749 shs	29,788 shs
ORIC Oric Pharmaceuticals	$11.27 +2.4%	$8.82	$3.90 ▼ $14.67	$959.32M	1.54	781,808 shs	180,845 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMRX Chimerix	0.00%	0.00%	0.00%	-0.06%	+848.99%
IMAB I-Mab	0.00%	-1.41%	-16.00%	+145.61%	+46.85%
LENZ LENZ Therapeutics	0.00%	-2.77%	+12.66%	+39.90%	+57.25%
ORIC Oric Pharmaceuticals	0.00%	-0.81%	+18.26%	+126.08%	+7.73%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMRX Chimerix	0.6504 of 5 stars	1.0	0.0	4.1	0.0	1.7	0.6
IMAB I-Mab	2.8855 of 5 stars	3.7	3.0	0.0	2.3	1.7	0.6
LENZ LENZ Therapeutics	1.2333 of 5 stars	3.6	0.0	0.0	1.7	0.8	0.0
ORIC Oric Pharmaceuticals	4.4656 of 5 stars	4.5	1.0	4.4	1.4	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMRX Chimerix	2.00	Hold	$8.53	-0.08% Downside
IMAB I-Mab	3.33	Buy	$6.00	181.69% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	37.65% Upside
ORIC Oric Pharmaceuticals	3.00	Buy	$18.57	64.79% Upside

Current Analyst Ratings Breakdown

Latest IMAB, LENZ, ORIC, and CMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/8/2025	ORIC Oric Pharmaceuticals	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00
6/23/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/29/2025	ORIC Oric Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$20.00
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/6/2025	ORIC Oric Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$15.00 ➝ $12.00
5/6/2025	ORIC Oric Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/5/2025	ORIC Oric Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00 ➝ $21.00

(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMRX Chimerix	$212K	3,778.71	N/A	N/A	$2.17 per share	3.94
IMAB I-Mab	$3.89M	44.71	N/A	N/A	$2.47 per share	0.86
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	$3.45 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMRX Chimerix	-$82.10M	-$0.99	N/A	N/A	N/A	N/A	-50.78%	-44.94%	8/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.81%	-18.63%	8/27/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)
ORIC Oric Pharmaceuticals	-$127.85M	-$1.87	N/A	N/A	N/A	N/A	-51.14%	-46.29%	8/11/2025 (Estimated)

Latest IMAB, LENZ, ORIC, and CMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ORIC Oric Pharmaceuticals	-$0.46	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/5/2025	Q1 2025	ORIC Oric Pharmaceuticals	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMRX Chimerix	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
ORIC Oric Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMRX Chimerix	N/A	6.33	6.33
IMAB I-Mab	N/A	22.35	22.35
LENZ LENZ Therapeutics	N/A	23.09	23.09
ORIC Oric Pharmaceuticals	N/A	12.00	12.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMRX Chimerix	45.42%
IMAB I-Mab	38.38%
LENZ LENZ Therapeutics	54.32%
ORIC Oric Pharmaceuticals	95.05%

Insider Ownership

Company	Insider Ownership
CMRX Chimerix	13.10%
IMAB I-Mab	22.10%
LENZ LENZ Therapeutics	6.90%
ORIC Oric Pharmaceuticals	5.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMRX Chimerix	90	93.80 million	78.15 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A
ORIC Oric Pharmaceuticals	80	85.22 million	80.49 million	Optionable

IMAB, LENZ, ORIC, and CMRX Headlines

Recent News About These Companies

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

July 15, 2025 | finance.yahoo.com

Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy?

July 15, 2025 | zacks.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock ... - Nasdaq

July 13, 2025 | nasdaq.com

Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy?

July 11, 2025 | zacks.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Down 4.9% - Here's What Happened

July 11, 2025 | marketbeat.com

Ladenburg Thalmann Initiates Coverage of ORIC Pharmaceuticals (ORIC) with Buy Recommendation

July 9, 2025 | msn.com

Oric Pharmaceuticals (NASDAQ:ORIC) Now Covered by LADENBURG THALM/SH SH

July 8, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Consensus Recommendation of "Buy" from Analysts

July 6, 2025 | marketbeat.com

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635 (c) (4) - Morningstar

July 5, 2025 | morningstar.comM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Metastatic Prostate Cancer Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 3, 2025 | theglobeandmail.com

Oric Pharmaceuticals (NASDAQ:ORIC) Trading 10% Higher - Time to Buy?

July 2, 2025 | marketbeat.com

Oric Pharmaceuticals Inc. Advanced Charts | ORIC | Barron's

June 28, 2025 | barrons.com

Oric Pharmaceuticals Shows Market Leadership With Jump To 93 RS Rating

June 25, 2025 | msn.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $10,340.00 in Stock

June 25, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Dominic Piscitelli Sells 1,034 Shares

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) CFO Sells $340,893.00 in Stock

June 24, 2025 | marketbeat.com

Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up Following Insider Buying Activity

June 24, 2025 | marketbeat.com

Angie You Purchases 1,403 Shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock

June 24, 2025 | insidertrades.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 26,597 Shares

June 23, 2025 | marketbeat.com

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Director Angie You Acquires 1,403 Shares

June 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
The Meteoric Rise of Rocket Lab: A Space Stock to Watch
By Ryan Hasson | July 11, 2025
View The Meteoric Rise of Rocket Lab: A Space Stock to Watch
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
3 Infrastructure Stocks Riding the U.S. Building Boom
By Chris Markoch | July 14, 2025
View 3 Infrastructure Stocks Riding the U.S. Building Boom
PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?
By Thomas Hughes | July 19, 2025
View PepsiCo Bottomed Out—Time to Chugalug This Blue-Chip Buy?

IMAB, LENZ, ORIC, and CMRX Company Descriptions

Chimerix NASDAQ:CMRX

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

I-Mab NASDAQ:IMAB

$2.13 +0.03 (+1.43%)

As of 12:34 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

LENZ Therapeutics NASDAQ:LENZ

$33.85 +0.13 (+0.37%)

As of 12:34 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Oric Pharmaceuticals NASDAQ:ORIC

$11.27 +0.26 (+2.36%)

As of 12:34 PM Eastern

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time